Ananth, J.V., Horodesky, J., Lechman, H.E. and Bon, T.A. (1970) Effect of withdrawal on chronically hospitalized psychiatric patients. Laval Medical, 41, 934-8.
Arana, G.W., Goff, D.C., Baldessarini, R.l., et al (1988) Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. American Journal of Psychiatry, 145, 993-996.
Arana, G.W., Teicher, M.H., Baldessarini, R.J. (1987) The utility of the dexamethasone suppression test. Archives of General Psychiatry, 44:95-96.
Avissar, S. & Schreiber, G. (1989) Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorder and for the treatment of the extrapyramidal side effects of neuroleptics. Biological Psychiatry, 26, 113-130.
Ayd, F. (1961) A survey of drug-induced extrapyramidal reactions. Journal of American Medical Association, 175, 1054-1060.
Ayd, F.J. Jr. (1974) Do antiparkinson drugs interfere with the therapeutic effects of neuroleptics? Int. Drug Ther News, 9, 29-32.
Baker, L.A., Cheng, L.Y., Amara, I.B. (1983) The withdrawal of benztropine mesylate in chronic schizophrenic patients. British Journal of Psychiatry, 143, 584-590.
Barnes, T.R.E. (1988) Tardive dyskinesia. British Medical Journal Clinical Research Ed., 296 (6616), 150-151.
Barnes, T.R.E. (1990) Comment on the WHO consensus statement. British Journal of Psychiatry, 156, 413-414.
Bartholini, G., Stadler, H. &Lloyd, K.G. (1973) Cholinergic-dopaminergic interaction in the extrapyramidal system. In Progress in the treatment of Parkinsonism (ed. D.B. Calne), pp 233-241. New York: Raven Press.
Bell, R.C.H. & Smith, R.C. (1978) Tardive dyskinesia: Characterization and prevalence in a statewide system. Journal of Clinical Psychiatry, 39, 39-47.
Bezchlibnyk-Butler, K. & Jeffries, J.J. (1991) Clinical Handbook of Psychotropic Drugs. Toronto ON: Hogrefe & Huber.
Bezchlibnyk-Butler, K. & Remington, G.J. (1994) Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Canadian Journal of Psychiatry, 39, 74-84.
Binder, R.I. & Levy, R. (1981) Extrapyramidal reactions in Asians. American Journal of Psychiatry, 138, 1243-1244.
Birket-Smith, E. (1974) Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurologica Scandinavica, 50, 801-811.
Birket-Smith, E., & Andersen, J.V. (1973) Treatment of side-effects of levodopa. Lancet, 1, 431.
Birket-Smith, E. (1974) Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurologica Scandinavica, 50, 801-811.
Bolin, R.R. (1960) Psychiatric manifestations of artane toxicity. Journal of Nervous and Mental Disease, 131, 256-259.
Bolvig Hansen, L., Elley, J., Rosted Christensen, T., et al (1979) Plasma levels of perphenazine and its major metabolites during simulataneous treatment with anticholinergic drugs. British Journal of Clinical Pharmacology, 7, 75-80.
Boyer, W.F., Bakalar, N.H. & Lake, C.R. (1987) Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. Journal of Clinical Psychopharmacology, 7, 164-166.
Burnett, G.B., Prange, A.J., Wilson, I.C., Jolliff, L. A., Creese, J.C. & Snyder, S.H. (1980) Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology, 6, 109-120.
Cant, J.S. (1969) Iatrogenic eye disease. Practitioner, 202, 787-795. Carodoc-Davies, G., Mankes, D.B.& Clarkson, H.O. (1986) A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Australia & New Zealand Journal of Psychiatry, 20, 225-232.
Caroli, F., Littre-Poirier, M.F., Ginestet, D. & Deniker, P. (1975) Essai d’interruption des antiparkinsoniens dans les traitements neuroleptiques au long cours. Encephale, 1, 69-74.
Case, D.E., Gerlach, J. & Christensson, E. (1980) Dopamine, acetylcholine and GABA effects in acute dystonia in primates. Psychopharmacology, 33, 1-5.
Casey, D.E. (1987) Sensitization and tolerance to long-term neuroleptic treatment in monkeys, in Proceedings of the American College of Neuropsychopharmacology, Nashville, Tenn, ACNP, p. 157.
Casey, D.E. (1992) Acyte neuroleptic-induced dystonia. In Disorders of Movement in Psychiatry and Neurology (eds. A.B. Joseph et al), pp. 106-110. Cambridge: Blackwell.
Casey, D.E. (1994) Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatrica Scandinavica, 89 (suppl 380), 14-20.
Casey, D.E., & Denney, D. (1977) Pharmacological characterization of tardive dyskinesia. Psychopharmacology, 54, 1-8.
Casey, D.E. & Keepers, G.A. (1988) Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In Psychopharmacology: Current Trends (eds. D.E. Casey & A.V. Christensen), pp. 74-93. New York: Springer.
Chouinard, G., de Montigny, C. & Annable, L. (1979) Tardive dyskinesia and antiparkinsonian medication. American Journal of Psychiatry, 136, 228-229.
Clarke, A.F. & Holden, N.L. (1987) The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospital inpatients. British Journal of Psychiatry, 150, 88-89.
Crane, G. E. (1973). Persistent dyskinesia. British Journal of Psychiatry, 122, 395-404. Crawshaw, J.A. & Mullen, P.E. (1984) A study of benzhexol abuse. British Journal of Psychiatry, 145, 300-3.
Crowley, T.J., Hoehn, M.M., Rutledge, C.O., et al (1978) Dopamine excretion and vulnerability to drug-induced parkinsonism. Archives of General Psychiatry, 35, 97-104. Dilsaver, S.C. (1988) Antimuscarinic agents as substances of abuse: a review. Journal of Clinical Psychopharmacology, 8, 14-22.
Dimascio, A. & Demirgian, E. (1970) Antiparkinson drug overuse. Psychosomatics, 11, 596-601.
Double, D.B., Warren, G.C., Evans, M. & Rowlands, M.P. (1993) Efficacy of maintenance use of anticholinergic agents. Acta Psychiatrica Scandinavica, 88, 381-384.
Dukes, M.N.G. (1984) Meyler’s Side effects of Drugs, 12th edition, Elsevier.
Duvoisin, R.C. (1967) Cholinergic-dopaminergic antagonism in parkinsonism. Advances in Neurology, 17, 124-136.
Duvoisin, R.C. & Katz, R. (1968) Reversal of central anticholinergic syndrome in man by physostigmine. Journal of the American Medical Association, 206, 1963-1965.
Editorial (1974) Mental changes in Parkinsonism. British Medical Journal, 2, 1-2. Ehringer, H. & Hornykiewicz, O. (1960) Verteilung von noradrenalin und dopamin (3-hydroxytramin) im gehirn des menschen and ihr verhalten bei erkrankungen des extrapyramidalen systems. Klinische Wochenschrift, 38, 1236-1239.
El-Yousef, M.K., Janowsky, D.S., Davis, J.M. & Scherke, H.J. (1972) Reversal of benztropine toxicity by physostigmine. Journal of the American Medical Association, 220, 125.
Fahn, S. And David, E. (1974) Oro-facio-lingual dyskinesia due to anticholinergic medication. Transactions of the American Neurological Association, 97, 277-279.
Fann, W.E. & Lake, C.R. (1974) On the coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System, 35, 324-326.
Fayen, M., Goldman, M.B., Moulthrop, M.A. & Luchins, D.J. (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. American Journal of Psychiatry, 145, 483-486.
Fleming, P., Makar, H. & Hunter, K.R. (1970) Levodopa in drug-induced extra-pyramidal disorders. Lancet, 2, 1186.
Forsman, A. & Ohman, R. (1977) Applied pharmacokinetics of haloperidol in man. Current Therapeutics Research, 21, 396-408.
French, N.H. & Heninger, G.R. (1970) A short clinical rating scale for use by nursing personnel. I. Development and design. Archives of General Psychiatry, 23, 233-240.
Friedman, Z. & Newman, E. (1972) Benzhexol-induced blindness. British Medical Journal, 1, 605.
Ganzini, L., Heintz, R., Hoffman, W.F., Keepers, G.A. & Casey, D.E. (1991) Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. Journal of Geriatric Psychiatry and Neurology, 4, 222-225.
Garfinkel, P.E. & Stancer, H.C. (1976) L-dopa and schizophrenia. Canadian Psychiatric Association Journal, 21, 27-29.
Garver, D.L., Davis, J.M., Dekirmenjian, H., et al (1976) Pharmacokinetics of red blood cells phenothiazine and clinical effects. Archives of General Psychiatry, 33, 862-866.
Gautier, J., Jus, A., Villeneuve, A., et al (1977) Influence of the antiparkinsonian drugs on the plasma level of neuroleptics. Biological Psychiatry, 12, 389-399.
Gelenberg, A.J. (1984) Use and abuse of anticholinergic drugs in psychiatry. Hillside Journal of Clinical Psychiatry, 6, 148-55.
Gerlach, J. (1977) The relationship between Parkinsonism and tardive dyskinesia. American Journal of Psychiatry, 134, 781-784.
Gerlach, J., Reisby, N. & Randrup, A. (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the patholophysiology of tardive dyskinesia. Psychopharmacology (Berlin), 34, 21-35.
Gerlach, J. & Thorsen, K. (1976) The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. International Pharmacopsychiatry, 11, 1-7.
Gershon, S. & Olariu, J. (1960) JB 329-A new psychotomimetic: Its antagonisms by tetrahydroaminacrin and its comparison with LSD, mescaline, and sernyl. Journal of Neuropsychiatry, 1, 283-292.
Goldner, R.D. (1967). Scopolamine sleep treatment in private practice. International Journal of Neuropsychiatry, 40, 99-100.
Goldstein, B.J., Jordan, J.A. & Coleman, B. (1964) Prophylactic treatment of phenothiazine-induced extrapyramidal effects. J Fla Med Assoc, 51, 775-778.
Granacher, R.P., Baldessarini, R.J. (1975) Physostigmine - its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Archives of General Psychiatry, 32, 375-80.
Greil, W., Haag, H., Rossnagi, G., et al (1984) Effect of anticholinergics on tardive dyskinesia. British Journal of Psychiatry, 145, 304-310.
Grove, L. & Crammer, J.L. (1972) Benzhexol and side effects with long-acting fluphenazine therapy. British Medical Journal, 1, 276-279.
Haase, H-J. (1965) The relationship of neuroleptic action to extrapyramidal phenomena. In The Action of Neuroleptic Drugs (eds. H-J. Haase & P.A.J. Janssen), pp.56-103. Amsterdam: North-Holland Publishing Company.
Hornykiewicz, O. (1982) Brain transmitter changes in Parkinson’s disease. In Neurology II, Movement Disorder (eds. C.D. Marsden and S. Fahn), pp. 41-58. London: Butterworths. Horrocks, P.M., Vicary, D.J., Rees, J.E., Parkes, J.D. & Marsden, C.D. (1973) Anticholinergic withdrawal and benzhexol treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 36, 936-941
. Hughes, R.C., Polgar, J.G. & Weightman, J.N. (1971) Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs. British Medical Journal, 2, 487-491.
Inanga, K., Inoue, K., Tachibana, H., Oshima, M. & Kotorii, T. (1972) Effects of L-dopa in schizophrenia. Folia Psychiatrica et Neurologica, 26, 145-157.
Itil, T.M., Keskiner, A. & Holden, J.M.C. (1969) The Use of LSD and ditran in the treatment of therapy-resistant schizophrenics. Diseases of the Nervous System, 30, 93-103.
Itoh, Z., Aizawa, I. & Nakamura, T. (1980) Effect of dopamine and its antagonists on contractile activity of the lower esophageal sphincter and the stomach. Nippon Heikatsukin Gakkai Zasshi, 16, 99-107.
Javoy-Agid, F., Ruberg, M., Taquet, H., Bokobza, E, Agid, Y, Gaspar, P, Berger, B., N’Guyen-Legros, J., Alvarez, C, Gray, F, Escourolle, R, Scatton, B. & Rouquier, L. (1984) Biochemical neuropathology of Parkinson’s disease. Advances in Neurology, 40, 189-198. Jellinek, T., Gardos, G. & Cole, J.O. (1981) Adverse effects of antiparkinson drug withdrawal. American Journal of Psychiatry, 138, 1567-1571.
Johnson, D.A.W. (1972) The psychiatric side-effects of drugs. The Practitioner, 209, 320-326.
Johnson, D.A.W. (1973) The side effects of fluphenazine decanoate. British Journal of Psychiatry, 123, 519-522.
Johnson, D.A.W. (1975) Observations on the dose regimes of fluphenazine decanoate in maintenance therpay of schizophrenia. British Journal of Psychiatry, 126, 457-61.
Johnson, D.A.W. (1978) Prevalence and treatment of drug-induced extrapyramidal symptoms. British Journal of Psychiatry, 132, 27-30.
Johnstone, E.C., Crow, T.J., Frith, C.D. & Owens, D.G.C. (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine, 13, 513-527.
Johnstone, E.C., Crow, T.J., Frith, C.D. & Owens, D.G.C. (1988) The Northwick Park "Functional" Psychosis Study: Diagnosis and treatment response. Lancet, 11, 119-125.
Jus, A., Pineau, R., Lachance, R., Perchat, G., Jus, K., Pires, P. & Villeneuve, R. (1976) Epidemiology of tardive dyskinesia. Diseases of the Nervous System, 37, 257-261.
Kaminer, Y., Munitz, H. & Wijsenbeek, H. (1982) Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. British Journal of Psychiatry, 140, 473-474.
Kane, J.M. & Lieberman, J.A. (1987) Maintenance pharmacotherapy in schizophrenia. In: Psychopharmacology: The Third Generation of Progress (ed. H.Y. Melzer), pp. 1103-1109. New York: Raven Press.
Kane, J.M. & Smith, J.M. (1982) Tardive dyskinesia: prevalence and risk factors 1959-1979. Archives of General Psychiatry, 39, 473-481.
Kazamatsuri, H., Chien, C.P. & Cole, J.O. (1972) Therapeutic approaches to tardive dyskinesa. Archives of General Psychiatry, 27, 491-9.
Keepers, G.A. & Casey, D.E. (1987) Prediction of neuroleptic-induced dystonia. Journal of Clinical Psychopharmacology, 7, 342-345.
Keepers, G.A. & Casey, D.E. (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. American Journal of Psychiatry, 148, 85-89.
Keepers, G.A., Clappison, V.J. & Casey, D.E. (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry, 40, 1113-1117.
Kennedy, P.F., Hereshon, H.I., & McGuire, R.S. (1971) Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509-518.
Klawans, H.L. (1973) The pharmacology of extrapyramidal movement disorders. In Monograph in Neural Science (ed. M.M. Cohen), Basel: Skarger.
Klawans, H.L. & Rubovits, R. (1974) Effect of cholinergic and anticholinergic agents on tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry, 27, 941.
Klett, C., Point, P. & Caffey, E. (1972) Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Archives of General Psychiatry, 26, 374-379.
Kolakowska, T., Wiles, D.H., Gelder, M.G., et al (1976) Clinical significance of plasma chlorpromazine levels:II. Plasma levels of the drug: Some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment. Psychopharmacology, 49, 101-107.
Korczyn, A.D. & Goldberg, F.J. (1976) Extrapyramidal effects of neuroleptics. Journal of Neurology, Neurosurgery & Psychiatry, 39, 866-869.
Lake, C.R., Casey, D.E., McEvoy, J.P., et al (1986) The "pros" and "cons" of anticholinergic prophylaxis. Psychopharmacology Bulletin, 22, 981-984.
Land, W., Pinsky, D. & Salzman, C. (1991) Abuse and misuse of anticholinergic medication. Hospital and Community Psychiatry, 42, 580-581.
Lavin, M.R. & Rifkin, A. (1991a) Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects. Journal of Clinical Pharmacology, 31, 763-768.
Lavin, M.R. & Rifkin, A. (1991b) Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy. Journal of Clinical Pharmacology, 31, 769-777.
Lewander, T., Westerbergh, S-E. & Morrison, D. (1990) Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatrica Scandinavica, 82 (Suppl 358), 92-98.
Linnoila, M., Viukari, M., Vaisanen, K. & Auvinen, J. (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry, 137, 819-821.
Loga, S., Curry, S. & Lader, M. (1975) Interaction of orphenadrine and phenobarbitone with chlopromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology, 2, 197-208.
Macvicar, K. (1977) Abuse of antiparkinson drugs by psychiatric patients. American Journal of Psychiatry, 134, 809-811.
Manos, N. & Gkiouzepas. J. (1981) Discontinuing antiparkinson medication in chronic schizophrenics. at what cost to the patient? Acta Psychiatrica Scandinavica, 63, 28-32.
Manos, N., Gkiouzepas, J., and Logothetis, L. (1981) The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic treatment. American Journal of Psychiatry, 138, 184-188.
Manos, N., Lavrentiadis, G. & Gkiouzepas, J. (1986) Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Journal of Clinical Psychiatry, 47, 114-116.
Marsden, C.D. & Jenner, P. (1980) Pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychological Medicine, 10, 55-72.
Mason, D.K. & Chisholm, D.M. (1975) Salivary glands in health and disease. London: WB Saunders.
May, P.R.A & Simpson, G.M. (1980) Schizophrenia: Overview of treatment methods. In Comprehensive Textbook of Psychiatry, ed 3. (eds. H.I. Kaplan & A.M. Freedman), pp. 174-214. Baltimore: Williams & Wilkins.
McClelland, H.A. (1976) Discussion on assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology, Supplement, 3, 401-3.
McClelland, H.A., Blessed, G., Bhate, S., Ali, N. & Clarke, P.A. (1974) The abrupt withdrawal of anti-parkinson drugs in schizophrenic patients. British Journal of Psychiatry, 124, 151-9.
McEvoy, J.P. (1983) The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. Journal of Clinical Psychopharmacology, 3, 288-302.
Meltzer, H.Y., Matsuabara, S. & Lee, J.C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 238-246.
Mindham, R.H.S. (1976) Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. British Journal of Clinical Pharmacology, 3, 395-400.
Mindham, R.H.S., Gaind, R., Anstee, B.H., et al (1972) Comparison of amantidine, orphenadrine and placebo in the control of phenothiazine induced parkinsonism. Psychological Medicine, 2, 406-413.
Mindham, R.H.S., Lamb, P. & Bradley, R. (1977) A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. British Journal of Psychiatry, 130, 581-585.
Moleman, P., Schmitz, P.J.M. & Ladee, G.A. (1982) Extrapyramidal side effects and oral hoperiodol: an analysis of explanatory patient and treatment characteristics. Journal of Clinical Psychiatry, 43, 492-496.
Molloy, D.W. & Brooymans, M. (1989) Anticholinergic medication and cognitive functions in the elderly. Journal of Clinical and Experimental Gerontology, 110, 89-98.
Morselli, P.L., Zarifian, E., Cuche, H., Bianchetti, G., Cotterau, M.J., Deniker, P. (1980) Haloperidol plasma level monitoring in psychiatric patients. In Long Term Effects of Neuroleptics (ed. F. Cattabeni). New York: Raven Press.
Ogura, C., Kishimoto, A. & Hakao, T. (1976) Clinical effects of L-dopa on schizophrenia. Current Therapeutic Research, 20, 308-318.
Orlov, P., Kasparian, G., Dimascio, A., et al (1971) Withdrawal of antiparkinson drugs. Archives of General Psychiatry, 25, 410-412.
Parkes, J.D. (1981) Adverse effects of antiparkinsonian drugs. Drugs, 21, 341-53.
Perry, P.J., Pfohl, B.M. & Kelly, M.W. (1988) The relationship of haloperidol concentrations to therapeutic response. Journal of Clinical Psychopharmacology, 8, 38-43.
Piper, D.W. & Heap, T.R. (1972) Medical management of peptic ulcer with reference to anti-ulcer agents in other gastro-intestinal diseases. Drugs, 3, 366-403.
Potamianos, G. & Kellett, J.M. (1982) Anticholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients. British Journal of Psychiatry, 140, 470-472.
Pullen, G.P., Best, N.R. & Maguire, J. (1984) Anticholinergic drug abuse: a common problem? British Medical Journal, 289, 612-613.
Quinn N.P. (1984) Antiparkinsonian drugs today. Drugs, 28, 236-62.
Reunanen, M., Kaartinen, P. & Vaisanen, E. (1982) The influence of anticholinergic treatment on tardive dyskinesia caused by neuroleptic drugs. Acta Neurologica Scandinavica (suppl 90), 65, 278-279.
Rifkin, A., Quitkin, F., Kane, J., et al (1978) Are prophylactic antiparkinson drugs necessary? Archives of General Psychiatry, 35, 483-488.
Rifkin, A., Quitkin, F. & Klein, D.F. (1975) Akinesia - a poorly recognised drug-induced extrapyramidal behavioural disorder. Archives of General Psychiatry, 32, 672-674.
Rivera-Calimlim, L., Castaneda, L. & Lasagna, L. (1973) Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology & Therapeutics, 14, 978-986.
Rouchell, A.M. & Dixon, S.P. (1977) Trihexyphenidyl abuse. American Journal of Psychiatry, 134, 1315.
Scherf, D. (1973) Atropine in acute myocardial infarction. American Heart Journal, 86, 284.
Shader, R.I. & Greenblatt, D.J. (1971) Uses and toxicity of belladonna alkaloids and synthetic anticholinergics. Seminars in Psychiatry, 3, 449-476.
Simpson, G.M., Cooper, T.B., Bark, N., Sud, I. & Lee, H. (1980) Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry, 37, 205-208.
Simpson, G.M., Krakov, B.L., Mattke, D., St Phard, G. (1970) A controlled comparison of the treatment of schizophrenic patients when treated according to neuroleptic threshold or by clinical judgement. Acta Psychiatrica Scandinavica, 212, 38-43.
Singh, M.M. & Kay, S.R. (1975a) A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Psychopharmacologia, 43, 103-113.
Singh, M.M. & Kay, S.R. (1975b): A longitudinal comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Non therapeutic interactions with trihexyphenidyl. Theoretical - implications for potency differences. Psychopharmacologia, 43, 115-123.
Singh, M.M., and Kay, S.R. (1979) Therapeutic antagonism between anticholinergic anti-Parkinsonism agents and neuroleptics in schizophrenia: Implications for a neuropharmacological model. Neuropsychobiology, 5, 74-86.
Singh, M.M., Kay,S.R., & Opler, L.A. (1987) Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms in schizophrenia: Implications for psychobiological typing. Psychological Medicine, 17, 39-48.
Singh, M. & Smith, J. (1973) Reversal of some therapeutic effects of an antipsychotic agent by antiparkinson drug. Journal of Nervous and Mental Disease, 157, 50-58.
Smith, S.E. (1971) Mydriatic drugs for routine fundal infection. Lancet, 2, 837-839.
Smith, J.M. (1980) Abuse of antiparkinson drugs: A review of the literature. Journal of Clinical Psychiatry, 41, 351-354.
Sovner, R. & Di Mascio, A. (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs, In Psycholpharmacology: a genration of progress (eds. M.A. Lipton, A. Di Mascio & K.R. Killam), pp. 1021-1032. New York: Raven Press.
Sramek, J.J., Simpson, G.M., Morrison, R.I., et al (1986) Anticholinergic agents for prophylaxis of neuroleptic induced dystonic reactions: a prospective study. Journal of Clinical Psychiatry, 47, 305-309.
Stephens, D.A. (1967). Psychotoxic effects of benzhexol hydrochloride (Artane). British Journal of Psychiatry, 113, 213-218.
Stern, T.A. & Anderson, W.H.L. (1979) Benztropine prophylaxis of dystonic reactions. Psychopharmacology (Berlin), 61, 261-262.
Swett, C. (1975) Drug induced dystonia. American Journal of Psychiatry, 132, 532-534.
Swett, C., Cole, J.O., Shapiro, S., et al (1977) Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis, Archives of General Psychiatry, 34, 942-943.
Synder, S., Greenberg, D. & Yamamura, H. (1974) Antischizophrenic Drugs and Brain Cholinergic Receptors. Archives of General Psychiatry, 31, 58-61.
Tandon, R., & Greden, J.F. (1989) Cholinergic hyperactivity and negative schizophrenic symptoms: A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry, 46, 745-753.
Tandon, R., Greden, J.F. & Silk, F.R. (1988) Treatment of negative schizophrenic symptoms with trihexyphenidyl. Journal of Clinical Psychopharmacology, 8, 212-215.
Tandon, R., Mann, N.A., Eisner, W.H., et al (1989) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatric Research, 31, 235-241.
Tandon, R., Mann, NA, Eisner, W.H., Coppard, N. (1990) Effect of anticholinergic medication on positive and negative symptoms of medication-free schizophrenic patients. Psychiatric Research, 31, 235-241.
Tatro, D.S. (1993) Drug Interaction Facts. St Louise MO: Facts and Comparisons.
Turek, I. Kurland, A., Hanlon, T. & Bohm, M. (1972) Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs. British Journal of Psychiatry, 121, 605-612.
Un, K.M. & Finder, E. (1983) Neuroleptic dosage for Asians. American Journal of Psychiatry,140, 490-491.
Vale, S. & Espejel, M.A. (1971) Amantadine for dyskinesia tarda. New England Journal of Medicine, 2184, 673.
Watski, E.J. & Salzman, C. (1991) Psychotropic drug interactions. Hospital and Community Psychiatry, 42, 247-256.
Wells, B.G., Marken, P.A. & Rickman, L.A., et al (1989) Characterizing anticholinergic abuse in community mental health. Journal of Clinical Psychopharmacology, 9, 431-435.
Wilcox, J.A. & Tsuang, J. (1990) Psychological effects of amantadine on psychotic subjects. Neuropsychobiology, 23, 144-146.
Winer, J.A. & Bahn, S. (1967) Loss of teeth with antidepressant drug therapy. Archives of General Psychiatry, 16, 239-40.
Winslow, R.S., Stillner, V., Coons, A.J., et.al (1986) Prevention of acute dystonic reactions: a prospective study. Journal of Clinical Psychiatry, 143, 706-10.
Wood, B & Haq, E.V. (1971) An unusual case of atropine poisoning. British Journal of Clinical Practice, 25, 469-470.
World Health Organisation (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. British Journal of Psychiatry, 156, 412.
Yaryura-Tobias, J.A., Wolpert, A., Dana, L. & Merlis, J. (1970) Action of L-dopa in drug- induced extrapyramidalism.